Impaired CD4 T-cell Response to SARS-CoV-2: Rationale for PD-1 Blockade in Patients with Cancer and COVID-19?
Bérengère Salomé, Amir Horowitz
Abstract
Abstract Summary: Cancer is a strong risk factor for severe COVID-19 disease. In this issue of Cancer Discovery, Bilich and colleagues demonstrate impaired preexisting and newly generated CD4 T-cell response to SARS-CoV-2 in patients with cancer. See related article by Bilich et al., p. 1982.
Topics & Concepts
Coronavirus disease 2019 (COVID-19)CancerSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Blockade2019-20 coronavirus outbreakDiseaseMedicineBetacoronavirusVirologyImmunologyBiologyInternal medicineInfectious disease (medical specialty)ReceptorOutbreakCOVID-19 and healthcare impactsCancer Immunotherapy and BiomarkersCOVID-19 Clinical Research Studies